Regulation of IL-6 signaling by p53: STAT3- and STAT5-masking in p53- Val135-containing human hepatoma Hep3B cell lines

Journal of Immunology

Volumn 161, Issue 1, 1998, Pages 325-334

  Rayanade, Ravi J ^a   Ndubuisi, MacKevin I ^a   Etlinger, Joseph D ^a   Sehgal, Pravin B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PROTEIN P53; STAT3 PROTEIN; STAT5 PROTEIN;

ARTICLE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; ENZYME ACTIVITY; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TIME;

AMINO ACID SUBSTITUTION; CARCINOMA, HEPATOCELLULAR; CYTOKINES; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPIDERMAL GROWTH FACTOR; HUMANS; INTERFERON TYPE II; INTERLEUKIN-6; MILK PROTEINS; MUTATION; PHENOTYPE; PHOSPHATIDYLINOSITOL DIACYLGLYCEROL-LYASE; PHOSPHOLIPASE C; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TEMPERATURE; TIME FACTORS; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE; VALINE;

EID: 0031859080     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Mackiewicz, A., A. Koj, and P. B. Sehgal, eds. 1995. Interleukin-6-type cytokines. Ann. NY Acad. Sci. 762:1.
2. Oppenheim, J. J., J. L. Rossio, and A. J. H. Gearing, eds. 1993. Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. Oxford University Press, New York.
3. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415.
4. Schindlet, C., and J. E. Darnell, Jr. 1995. Transcriptional responses to polypeptide ligands: the Jak-STAT pathway. Annu. Rev. Biochem. 64:621.
5. Lai, C.-F., K. K. Morella, Y. Wang, S. Kumaki, D. Gearing, S. F. Zeigler, D. J. Tweardy, S. P. Campos, and H. Baumann. 1995. Function of hematopoietin receptor subunits in hepatic cells and fibroblasts. Ann. NY Acad. Sci. 762:189.
6. Ihle, J. N. 1996. STATs: signal transducers and activators of transcription. Cell 84:331.
7. Kishimoto, T., A. Akira, M. Narazaki, and T. Taga. 1995. Interleukin-6 family of cytokines and gp130. Blood 86:1243.
8. Ripperger, J. A., S. Fritz, K. Richter, G. M. Hocke, F. Lottspeoch, and G. H. Fey. 1995. Transcription factors Stat3 and Stat5b are present in rat liver nuclei late in an acute phase response and bind interleukin-6 response elements. J. Biol. Chem. 270:29998.
9. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A, Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin 6. Nature 352:345.
10. Levy, N. E. Yonish-Rouach, M. Oren, and A. Kimchi. 1993. Complementation by wild-type p53 of interleukin-6 effects on MI cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol. Cell. Biol. 13:7942.
11. Gottlieb, E., R. Haffuer, T, von Ruder, E. Wagner and M. Oren. 1994. Down regulation of wild-type p53 activity interferes with apoptosis of IL-3 dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13:1368.
12. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323.
13. Sood, A. K., J. S. Skilling, and R. E. Buller. 1997. Ovarian cancer genomic instability correlates with p53 frameshift mutations. Cancer Res. 57:1047.
14. Hung, J., and R. Anderson. 1997. p53: functions, mutations and sarcomas. Acta Orthop. Scand. 273(Suppl.):68.
15. Tashiro, H., C. Isacson, R. Levine, R. J. Kurman, K. R. Cho, and L. Hedrick. 1997. p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am. J. Pathol. 150:177.
16. Bogler, O., H. J. Huang, P. Kleihaus, and W. K. Cavenee. 1995. The p53 gene and its role in human brain tumors. Glia 15:308.
17. Hangaishi, A., S. Ogawa, N. Imamura, S. Miyawaki, Y. Muira, N. Uike, C. Shimazaki, N. Emi, K. Takeyama, S. Hirosawa, N. Kamada, Y. Kobayashi, Y. Takemoto, T. Kitani, K. Toyama, S. Ohtake, Y. Yazaki, R. Ueda, and H. Hirai. 1996. Inactivation of multiple tumor suppressor genes involved in negative regulation of the cell cycle, MTSI/p16INK4A/CDKN2, MTS2/p 15INK48, p53 and Rb genes in primary lymphoid malignancies. Blood 87:4949.
18. Yasuga, Y., S. Hirosawa, K. Yamamoto, J. Tomiyama, J. Nagata, and N. Aokia. 1995. N-ras and p53 gene mutations are very rare events in multiple myeloma. Int. J. Haematol. 62:91.
19. Borsellino, N., A. Belldegrun, and B. Bonavida. 1995. Endogenous interleukin 6 is a resistance factor for cis-diaminedichloroplatinum and etoposide mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. 55:4633.
20. Corradini, P., G. Inghirami, M. Astolfi, M. Ladetto, C, Voena, P. Ballerini, W. Gu, K. Nilsson, D. M. Knowles, M. Boccadoro, A. Pileri, and R. Dalla-Favera. 1994. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 8:758.
21. Williams, P. M., A. W. Kuypers, J. P. Meijerink, R. S. Holdrinet, and E. J. Mensink. 1993. Sporadic mutations of the p53 gene in multiple myeloma and no evidence for germline mutations in three familial multiple myeloma pedigrees. Leukemias 7:986.
22. Neri, A., L. Baldini, D. Trecca, L. Cro, E. Polli, and A. T. Maiolo. 1993. p53 mutation in multiple myeloma are associated with advanced forms of malignancy. Blood 81:128.
23. Preudhomme, C., T. Facon, M. Zandecki, M. Vanrumbeke, J. L. Lai, E. Nataf, M. W. Loucheur-Lefebvre, J. P. Kerckacrt, and P. Fenaux. 1992. Rare occurrence of p53 gene mutations in multiple myeloma. Br. J. Haematol. 81:440.
24. Shaulsky, G., N. Goldfinger, M. S. Tosky, A. J. Levine, and V. Rotter. 1991. Nuclear localization is essential for the activity of p53 protein. Oncogene 6:2055.
25. Shaulsky, G., N. Goldfinger, A. Peled, and V. Rotter. 1991. Involvement of wild type p53 protein in the cell cycle requires nuclear localization. Cell Growth Differ. 2:661.
26. Ostermeyer, A. G., E. Runko, B. Winkfield, B. Ahu, and U. M. Moll. 1996. Cytoplasmically sequestered wildtype p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc. Natl. Acad. Sci. USA 93:15190.
27. Moll, U. M., M. LaQuaglia, J. Bernard, and G. Riou. 1995. Wild type p53 protein undergoes cytoplasmic sequestration in differentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA 92:4407.
28. Moretta, A. 1997. Molecular mechanisms in cell-mediated cytotoxicity. Cell 90:-13.
29. Chen, H. L., and D. P. Carbone. 1997. p53 as a target for anticancer immunotherapy. Mol. Med. Today 3:160.
30. Nielobitek, G., A. Agathanggelou, P. Barber, L. A. Smallman, E. L. Jones, and L. S. Young. 1993. p53 overexpression and Epstein Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J. Pathol. 170:457.
31. Hald, J., N. Rasmussen, and M. W. Claesson. 1994. In vivo infiltration of mononuclear cells in squamous cell carcinoma of the head and neck correlates with the ability to expand tumor-infiltrating T cells in vitro and with the expression of MHC class 1 antigens on tumor cells. Can. Immunol. Immunother. 39:383.
32. Hald, J., N. Rasmussen, and M. W. Claesson. 1995. Tumor infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol. Immunother. 41:243.
33. Ropke, M., J. Hald, P. Guldberg, J. Zeuthen, L. Nergaud, L. Fugger, A. Svejgaard, S. Van Der Berg, H. W. Nijman, C. J. M. Malief, and M. W. Claesson. 1996. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild type p53-derived peptide. Proc. Natl. Acad. Sci. USA 93:14704.
34. Theobald, M., J. Biggs, D. J. Dittmer, A. J. Levine, and L. A. Sherman. 1995. Targetting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993.
35. Maacke, H., A. Kessler, W. Schmiegel, C. Roeder, I. Vogel, W. Deppert, and H. Kalthoff. 1997. Overexpression of p53 protein during pancreatitis. Br. J. Cancer 75:1501.
36. Ungar, S., A. Van-de-Meeren, L. Tammilehto, K. Linnainmaa, K. Mattson, and B. I. Gerwin. 1996. High levels of MDM2 are not correlated with the presence of wildtype p53 in human malignant mesothelioma cell lines. Br. J. Cancer 74:1534.
37. Gudas, J. M., H. Nguyen, T. Li, L. Sadzewics, R. Robey, K. Wosikowski, and K. H. Cowan. 1996. Drug resistant breast cancer cells frequently retain expression of a functional wild type p53 protein. Carcinogenesis 17:1417.
38. Bosari, S., G. Viale, M. Ronealli, D. Graziani, G. Borsani, A. K. Lee, and G. Coggi. 1995. p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. Am. J. Pathol. 147:790.
39. Tominaga, O., R. Hamelin, V. Trouvat, R. J. Salmon, G. Lesec, G. Thomas, and Y. Remvikos. 1993. Frequently elevated content of immunochemically defined wildtype p53 protein in colorectal adenomas. Oncogene 8:2653.
40. Ndubuisi, M. I., K. Patel, R. J. Rayanade, R. Romero, A. Mittleman, L. T. May, and P. B. Sehgal. 1998. Distinct classes of chaperoned IL-6 in human blood: differential immunological and biological availability. J. Immunol. 160:494.
41. Wang, L., R. Rayanade, D. Garcia, K. Patel, H. Pan, and P. B. Sehgal. 1995. Modulation of interleukin-6 induced plasma protein secretion in hepatoma cells by p53. J. Biol. Chem. 270:23159.
42. 135. Oncogene 8:3417-3419.
43. Zhang, X., J. Blenis, H. C. Li, C. Schindler, and S. Chen-Kiang. 1995. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267:1990.
44. Ram, P. A., and D. J. Waxman. 1997. Interaction of growth hormone-activated STATs with SH2 containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J. Biol. Chem. 272:17694.
45. Rayanade, R. J., K. Patel, M. Ndubuisi, S. Sharma, S. Omura, J. D. Etlinger, R. Pine, and P. B. Sehgal. 1997. Proteasome and p53-dependent masking of signal transducer and activator of transcription (STAT) factors. J. Biol. Chem. 272:4659.
46. Sehgal, P. B., J. E. Darnell, and I. Tamm. 1976. The inhibition by DRB (5,6-dichloro-1-β-D-ribofuranosylbenzimidazole) of hnRNA and mRNA production in HeLa cells. Cell 9:473.
47. Sehgal, P. B., D. S. Lyles, and I. Tamm. 1978. Superinduction of human fibroblast interferon production: further evidence for increased stability of interferon mRNA. Virology 89:186.
48. Horvath, C. M., Z. Wen, and J. E. Darnell, Jr. 1995. A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9:984.
49. Plant, T. W., R. G. Deeley, and G. Grieninger. 1983. Selective block of albumin gene expression in chick embryo hepatocytes cultured without hormones and its partial reversal by insulin. J. Biol. Chem. 258:15355.
50. Baumann, H., G. P. Jahreis, and K. K. Morella. 1990. Interaction of cytokine- and glucocorticoid-response elements of acute phase plasma protein genes. J. Biol. Chem. 265:22275.
51. Margulies, L., and P. B. Sehgal. 1993. Modulation of the human interleukin-6 (IL-6) promoter and transcription factor C/EBP (NF-IL6) activity by p53. J. Biol. Chem. 268:15096.
52. Haspel, R. L., M. Salditt-Georgieff, and J. E. Darnell, Jr. 1996. The rapid inactivation of nuclear tyrosine phosphorylated STAT1 depends upon a protein tyrosine phosphatase. EMBO J. 15:6262.
53. Klingmuller, U., U. Lorenz, L. C. Cantley, B. G. Neel, and H. F. Lodish. 1995. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 80:729.
54. David, M., H. E. Chen, S. Goelz, A. C. Larner, and B. G. Neel. 1995. Differential regulation of the α/3 interferon-stimulated Jak-STAT pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 15:7050.
55. David, M., G. Zhou, R. Pine, J. E. Dixon, and A. C. Larner. 1996. The SH2 domain containing tyrosine phosphatase PTP1D is required for interferon α/β-induced gene expression. J. Biol. Chem. 271:15862.
56. Tonks, N. K., and B. G. Neel. 1996. From form to function: signalling by protein tyrosine phosphatases. Cell 87:365.
57. Scharenberg, A. M., and J. P. Kinet. 1996. The emerging field of receptor-mediated inhibitory signaling: SHP or SHIP? Cell 87:961.
58. Pang, L., T. Sawada, S. J. Decker, and A. R. Saltiel. 1995. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factors. J. Biol. Chem. 270:13585.
59. Amson, R. B., M. Namani, J. P. Roperch, D. Israeli, L. Bouguelet, I. LeGall, M. Medhioub, G. Linares-Cruz, F. Lethrosne, P. Pasturaud, L. Piouffre, S. Prieur, L. Susini, V. Alvaro, P. Millasseau, C. Guidicelli, H. Bui, C. Massari, L. Cazes, F. Dufour, H. Bruzzoni-Giovanelli, H. Owadi, C. Hennion, G. Charpak, J. Dausset, F. Calvo, M. Oren, D. Cohen, and A. Telerman. 1996. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the Drosophila seven in absentia gene. Proc. Natl. Acad. Sci. USA 93:3953.
60. Boulton, T. G., N. Stahl, and G. D. Yancopoulos. 1994. Ciliary neurotrophic factor/leukemia inhibitor factor/interleukin 6/oncostatin M family of cytokines induces tyrosine phosphorylation of a common set of proteins overlapping those induced by other cytokines and growth factors. J. Biol. Chem. 269:11648.
61. Smith, R. J., L. M. Sam, J. M. Justen, G. L. Bundy, G. A. Bala, and J. E. Bleasdale. 1990. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: effect of novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J. Pharmacol. Exp. Ther. 253:688.
62. 2+ inflow. Biochem. Pharmacol 49:1373.
63. Kiss, Z., and M. Tomono. 1995. Compound D609 inhibits phorbol ester-stimulated phopholipase D activity and phospholipase C-mediated phosphatidylethanolamine hydrolysis. Biochim. Biophys. Acta 1259:105.
64. Kaltschmidt, C., B. Kaltschmidt, and P. A. Baeuerle. 1995. Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons. Proc. Natl. Acad. Sci. USA 92:9618.
65. Kaltschmidt, C., B. Kaltschmidt, T. Henkel, H. Stockinger, and P. A. Baeuerle. 1995. Selective recognition of the activated form of transcription factor NF kappa B by a monoclonal antibody. Biol. Chem. Hoppe-Seyler 375:9.
66. Scherer, D. C., J. A. Brockman, Z. Chen, T. Mainatis, and D. W. Ballard. 1995. Signal induced degradation of I κ B α requires site specific ubiquitination. Proc. Natl. Acad. Sci USA 92:11259.
67. Chen, Z., J. Hagler, V. J. Palombella, F. Melandri, D. Scherer, D. Ballard, and T. Maniatis. 1995. Signal induced site-specific phosphorylation targets I κ B α to the ubiquitin-proteasome pathway. Genes Dev. 9:1586.
68. Yu, C. L., and S. J. Burakoff. 1997. Involvement of proteasomes in regulating Jak-STAT pathways upon interleukin-2 Stimulation. J. Biol. Chem. 272:14017.
69. Kharitonenkov, A., Z. Chen, I. Sures, H. Wang, J. Schilling, and A. Ullrich. 1997. A family of proteins that inhibit signalling through tyrosine kinase receptors. Nature 386:181.
70. Starr, R., T. A. Willison, E. M. Viney, L. J. L. Murray, J. R. Rayner, B. J. Jenkins, T. J. Gonda, W. S. Alexander, D. Metcalf, N. A. Nicola, and D. J. Hilton. 1997. A family of cytokine-inducible inhibitors of signalling. Nature 387:917.
71. Endo, T. A., M. Masuhara, M. M. Yokouchi, R. Suzuki, H. Sakamoto, K. Mitsui, A. Matsumoto, S. Tanimura, M. Ohtsubo, H. Misawa, T. Miyazaki, N. Leonor, T. Taniguchi, T. Fujita, Y. Kanakura, S. Komiya, and A. Yishimura. 1997. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387:921.
72. Naka, T., M. Narazaki, M. Hirata, T. Matsumoto, S. Minamoto, A. Aono, N. Nishimoto, T. Kajita, T. Taga, K. Yoshizaki, S. Akira, and T. Kishimoto. 1997. Structure and function of a new STAT-induced STAT inhibitor. Nature 387:924.
73. Fiscella, M., H. Zhang, S. Fan, K. Sakaguchi, S. Shen, W. E. Mercer, G. F. vande Woude, P. M. O'Connor, and E. Appella. 1997. Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53 dependent manner. Proc. Natl. Acad. Sci. USA 94:6048.
74. Chung, C. D., J. Liao, B. Liu, X. Rao, P. Jay, P. Berta, and K. Shuai. 1997. Specific inhibition of Stat3 signal transduction by PIAS3. Science 278:1803.
75. Noh, D.-Y., S. H. Shin, and S. G. Rhee. 1995. Phosphatide-specific phospholipase C and mitogenic signalling. Biochim. Biophys. Acta 1242:99.